• Je něco špatně v tomto záznamu ?

Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII

T. Knedlík, B. Vorlová, V. Navrátil, J. Tykvart, F. Sedlák, Š. Vaculín, M. Franěk, P. Šácha, J. Konvalinka,

. 2017 ; 7 (9) : 1362-1378. [pub] 20170829

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031952

Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031952
003      
CZ-PrNML
005      
20171103105043.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/2211-5463.12276 $2 doi
035    __
$a (PubMed)28904865
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Knedlík, Tomáš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
245    10
$a Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII / $c T. Knedlík, B. Vorlová, V. Navrátil, J. Tykvart, F. Sedlák, Š. Vaculín, M. Franěk, P. Šácha, J. Konvalinka,
520    9_
$a Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vorlová, Barbora $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. First Faculty of MedicineCharles UniversityPragueCzech Republic.
700    1_
$a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
700    1_
$a Tykvart, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic. Present address: Donnelly Centre for Cellular and Biomolecular ResearchUniversity of TorontoTorontoONCanada.
700    1_
$a Sedlák, František $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. First Faculty of MedicineCharles UniversityPragueCzech Republic. Department of Genetics and MicrobiologyFaculty of ScienceCharles UniversityPragueCzech Republic.
700    1_
$a Vaculín, Šimon $u Department of Normal, Pathological and Clinical PhysiologyThird Faculty of MedicineCharles UniversityPragueCzech Republic.
700    1_
$a Franěk, Miloslav $u Department of Normal, Pathological and Clinical PhysiologyThird Faculty of MedicineCharles UniversityPragueCzech Republic.
700    1_
$a Šácha, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic.
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesPragueCzech Republic. Department of BiochemistryFaculty of ScienceCharles UniversityPragueCzech Republic.
773    0_
$w MED00184538 $t FEBS open bio $x 2211-5463 $g Roč. 7, č. 9 (2017), s. 1362-1378
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28904865 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171103105138 $b ABA008
999    __
$a ind $b bmc $g 1255545 $s 992979
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 7 $c 9 $d 1362-1378 $e 20170829 $i 2211-5463 $m FEBS open bio $n FEBS Open Bio $x MED00184538
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...